Cardiovascular Disease

Nathan D Wong, PhD, MPH, renowned in the field of preventive cardiology, reviewed for Patient Care the history of the field and his own pivotal contributions and also paid tribute to his lifetime mentors.

Assessment of CVD risk is the foundation of primary prevention and integral to primary care. Brush up on the fundamental tools of risk estimation from the ACC/AHA guidelines.

A head-to-head study found the 2 drug classes equally effective first-line therapies but ARBs, though prescribed less often, proved somewhat safer.

The FDA requests removal of pregnancy contraindication from statin prescribing information based on comprehensive reviews that found no evidence of an increase in birth defects.

The short slide show summarizes 9 pearls on preventive cardiology from the landmark ACC/AHA 2019 guideline on primary CVD prevention.

In patients with stable vascular disease from the COMPASS trial, the combination of rivaroxaban and aspirin effectively reduced ischemic events despite multiple comorbidities and polypharmacy.

What does the latest research say about the association between mental health and cardiovascular disease? Scroll through our quick slideshow for an overview.

The first nonsteroidal mineralocorticoid receptor antagonist to be approved for adults with T2D-associated CKD fills a significant treatment void for millions of patients.

A recent study found that the use of statins in patients with newly diagnosed T2D reduced incidence of cardiovascular disease and death, particularly among older patients.

Using data from wearable devices that track physiologic changes caused by viral illness, researchers observed prolonged deviation from baseline resting heart rate in study participants.

The SGLT-2 inhibitor class, originally approved as antihyperglycemic agents for T2D, has proven "pluripotent," adding indications for related conditions. Test your knowledge of a few basic facts.

Empagliflozin, already indicated to improve outcomes in patients with HFrEF, reduced risk of a composite of CV death or hospitalization for HF in adults HFpEF, marking a potential therapeutic milestone.

Diabetes investigator John Buse, MD, PhD, says laser focus on reducing T2D risk factors is equally as important as using the next right drug against the disease.

Dr Buse’s in-depth review of the GRADE study is followed by a discussion of the keen need for more comparative research and the many new questions the results have raised about optimal T2D therapy.

Preliminary GRADE study results showed that liraglutide and insulin glargine added to metformin maintained A1c level in target range longer than glimepiride or sitagliptin.

ADA 2021: The investigational exendin-4-based GLP-1 RA was associated with a 27% decrease in risk for a CV event and a 32% reduction in risk for CKD progression.

ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not GLP-1 receptor agonists were on board at study baseline.

Adults in their 30s and 40s who had high BMI in adolescence were at highest risk for type 2 diabetes and early MI, regardless of adult BMI, after 24 years of follow-up, a new study finds.

The American Diabetes Association 2021 Scientific Sessions run from June 25 to 29. This short slide show highlights 6 clinical trial updates that are a "must see" for primary care clinicians.

Although over 90% of adults with a history of CVD reported knowing that smoking can cause heart disease, nearly 30% reported current tobacco use in a new study.

Assessment of prediabetes subphenotypes is a novel approach to better screening, prevention, and treatment for patients at risk of progression to T2D. Find out how much you know about it.

New research proposes pathophysiology-based subphenotyping of individuals at increased risk for T2D; 6 are suggested to help refine screening, prevention, and treatment.

Poll: 91% of women don’t know heart disease is the #1 cause of death in women and 81% aren’t aware that the Pap test screens only for cervical cancer. Counseling and education are needed.

Magnet technology in the iPhone 12 Pro Max that allows the device to charge wirelessly can significantly impair function of a variety of cardiac implantable electronic devices.

In people without diabetes and considered low risk for CVD, A1c was associated in a graded, positive fashion with subclinical atherosclerosis, even at prediabetes levels.

SGLT-2 inhibitor investigator Mikhail Kosiborod, MD, answers questions about patient selection for the class of drugs, now with approval to treat much more than type 2 diabetes.

The landmark Diabetes Prevention Program (DPP) trial and follow-up studies proved that risk of T2D can be reduced in patients at high risk for the disease. Do you know by how much?

Four major cardiology organizations stand behind increased government action to eradicate tobacco use worldwide. Click here for a summary of why, why now, and how.

Adults with OCD were more than 3 times as likely to have an ischemic stroke after age 40 than those without the disorder, according to a study published in Stroke.

Mikhail Kosiborod, MD, a lead investigator for clinical trials of SGLT2 inhibitors, traces the class history from antidiabetic agents to guideline-recommended multidisease treatments.